End-of-day quote
Other stock markets
|
||
- USD | - |
|
06-27 | GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650 | MT |
06-27 | GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study | DJ |
Sales 2022 | - | Sales 2023 | - | Capitalization | 10.56M 833M |
---|---|---|---|---|---|
Net income 2022 | -20M -1.58B | Net income 2023 | -7M -552M | EV / Sales 2022 | - |
Net cash position 2022 | 16.33M 1.29B | Net cash position 2023 | 13.91M 1.1B | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.35
x | P/E ratio 2023 |
-1.36
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.34% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 61 | 12/01/21 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 13/12/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 30/04/23 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 10/11/20 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 12/01/21 |
1st Jan change | Capi. | |
---|---|---|
+55.32% | 815B | |
+43.16% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.19% | 242B | |
+2.17% | 224B | |
+13.37% | 218B | |
+8.48% | 168B |